Gut

Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows

Retrieved on: 
Thursday, May 19, 2022 - 5:28pm

(Credit: Feinstein Institutes)

Key Points: 
  • (Credit: Feinstein Institutes)
    The preclinical study published in the journal Molecular Medicine shows that famotidine, a histamine 2 receptor (H2R) antagonist, prevents cytokine storm in mice.
  • Investigators found that increased vagus nerve signals were why famotidine injections stopped cytokine storms.
  • By cutting the vagus nerve, known as a vagotomy, it prevented the ability of famotidine to stop the cytokine storms.
  • Now these new results point to a role of the vagus nerve inflammatory reflex in suppressing cytokine storm during COVID-19.

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022 - 1:00pm

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

Retrieved on: 
Monday, March 14, 2022 - 12:00am

SHANGHAI, March 13, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that it has entered into a license agreement with Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) to develop and commercialize NEFECON for the treatment of primary IgA nephropathy (IgAN) in South Korea, expanding its license in addition to rights held in Greater China and Singapore. The deal signals the Company's latest efforts to further enhance its international commercial footprint.

Key Points: 
  • "South Korea's sophisticated healthcare model enables innovative medicines such as NEFECON to have a higher potential likelihood of healthcare coverage once approved.
  • Under the terms of the agreement, Calliditas receives an initial upfront payment of USD$3 million at signing of the agreement.
  • In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON in Mainland China, Hong Kong, Macau, Taiwan and Singapore.
  • The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.

Famotidine (Pepcid) Clinical Trial Shows Reduction in COVID-19 Symptoms

Retrieved on: 
Thursday, February 10, 2022 - 9:18pm

Patients who took famotidine in this trial experienced a decrease of inflammation within the body and reported earlier alleviation of symptoms.

Key Points: 
  • Patients who took famotidine in this trial experienced a decrease of inflammation within the body and reported earlier alleviation of symptoms.
  • View the full release here: https://www.businesswire.com/news/home/20220210005964/en/
    The famotidine clinical trial was designed to keep participants out of the hospital by enabling participation from home.
  • We closely monitored patients in this fully remote clinical trial while protecting their safety and that of health care providers in pandemic conditions.
  • The trial, which was launched in January 2021, was an entirely remote, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of famotidine in diverse patient populations.

MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas

Retrieved on: 
Thursday, January 13, 2022 - 6:00pm

MaaT Pharma (EURONEXT: MAAT - the Company), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by KBC Securities, Kempen and Portzamparc / Groupe BNP Paribas.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT - the Company), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by KBC Securities, Kempen and Portzamparc / Groupe BNP Paribas.
  • With a research report named chec et MaaT pour le cancer, Portzamparc / Groupe BNP Paribas today initiates coverage of MaaT Pharma with a Buy recommendation.
  • February 28th, 2022, after stock market closes: publication of the 2021 revenues and cash position as of December 31st, 2021.
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.

Logi Analytics Announces Logi Spark 2021 Virtual Conference

Retrieved on: 
Wednesday, October 13, 2021 - 2:09pm

MCLEAN, Va., Oct. 13, 2021 /PRNewswire/ -- Logi Analytics , an insightsoftware company and the leading provider of embedded analytics solutions for software teams, today announced Logi Spark 2021, a two-day online event that offers a variety of sessions geared toward sparking innovation and knowledge sharing.

Key Points: 
  • MCLEAN, Va., Oct. 13, 2021 /PRNewswire/ -- Logi Analytics , an insightsoftware company and the leading provider of embedded analytics solutions for software teams, today announced Logi Spark 2021, a two-day online event that offers a variety of sessions geared toward sparking innovation and knowledge sharing.
  • The Logi Spark 2021 Virtual Conference will take place October 19-20, 2021.
  • "Logi Spark 2021 creates a forum for those in the data analytics community to share knowledge, insights and best practices to help achieve more success."
  • Mico Yuk, Co-Founder and CEO of BI Brainz , presenting "Bringing Data to Life: The Gut, the Emotion, and the Data"
    Justin Gawthrop, Manager, Customer Success Operations at Logi Analytics , presenting on "DevOps Integration: Better Analytics, Faster Delivery"
    Charles Caldwell, VP, product management and Ardeshir Ghanbarzadeh, Director, Product Marketing at Logi Analytics , presenting on "Predictive vs. Augmented Analytics: Analytics Strategies for the Future"
    In addition to the Logi Spark 2021 Virtual Conference, Logi Analytics recently announced its 2021 State of Analytics: How Data Literacy Improves Decision-Making report.

NUTRISHOP® Dives Deep into Optimal Wellness with Comprehensive Gut Formula

Retrieved on: 
Wednesday, June 2, 2021 - 6:28pm

HENDERSON, Nev., June 2, 2021 /PRNewswire/ -- NUTRISHOP, a national nutrition, weight-loss, wellness and supplement retail franchise, today announced the launch of Gut Formula by NU-TEK Nutrition at NUTRISHOP stores nationwide and online at www.NutrishopUSA.com .

Key Points: 
  • HENDERSON, Nev., June 2, 2021 /PRNewswire/ -- NUTRISHOP, a national nutrition, weight-loss, wellness and supplement retail franchise, today announced the launch of Gut Formula by NU-TEK Nutrition at NUTRISHOP stores nationwide and online at www.NutrishopUSA.com .
  • "The gut plays such a vital role in people's overall health and wellness, but it is often overlooked," said Bryon McLendon, CEO and Founder of Nutrishop.
  • We are definitely excited to be able to offer such a comprehensive and innovative product like Gut Formula exclusively to our Nutrishop customers!"
  • For more information about Gut Formula or other wellness products, please visit a local Nutrishop store or head to NutrishopUSA.com .

Health-Ade Believes in the Power of Gut Health, Launches A Multimillion-Dollar Marketing Campaign to Close the Gap on Consumer Knowledge

Retrieved on: 
Wednesday, May 26, 2021 - 2:03pm

Despite the gap in knowledge, consumers are beginning to realize there's something critical happening in their digestive systems.

Key Points: 
  • Despite the gap in knowledge, consumers are beginning to realize there's something critical happening in their digestive systems.
  • The campaign goal: demystifying gut health for a universal audience that goes beyond kombucha die-hards.
  • The brand refresh and campaign expand the conversation about gut health by unpacking the gut's influential role in our everyday lives (your cognition, mood, energy, etc.)
  • Health-Ade creates feel-good, bubbly beverages with gut health benefits so you can follow your gut and show the world what you're made of.

New health survey from PrecisionBiotics reveals fear about life after lockdown

Retrieved on: 
Wednesday, April 14, 2021 - 9:00am

How does it help or hinderthe ability to live well, work effectively and enjoy life?

Key Points: 
  • How does it help or hinderthe ability to live well, work effectively and enjoy life?
  • According to people who suffer from poor gut health, it is fundamental.\nA recent survey of over 1,000 people conducted in March 2021 by PrecisionBiotics has revealed some extraordinary insights from the people who suffer with the symptoms of poor gut health.
  • Exercise or antidepressants.\nIt is alarming to find from this survey that over 50% of respondents have suffered from gut health problems for nearly half their life.
  • The programme includes weekly tips, recipes, nutritional advice, monthly check ins and personalised guidance from gut health advisors as well as a free symptom tracker.

New health survey from PrecisionBiotics reveals fear about life after lockdown

Retrieved on: 
Wednesday, April 14, 2021 - 9:00am

How does it help or hinderthe ability to live well, work effectively and enjoy life?

Key Points: 
  • How does it help or hinderthe ability to live well, work effectively and enjoy life?
  • According to people who suffer from poor gut health, it is fundamental.\nA recent survey of over 1,000 people conducted in March 2021 by PrecisionBiotics has revealed some extraordinary insights from the people who suffer with the symptoms of poor gut health.
  • Exercise or antidepressants.\nIt is alarming to find from this survey that over 50% of respondents have suffered from gut health problems for nearly half their life.
  • The programme includes weekly tips, recipes, nutritional advice, monthly check ins and personalised guidance from gut health advisors as well as a free symptom tracker.